US7665596034
© PR Newswire
07.12.2025
RIGL
LISTED
NASDAQ
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
News Preview
R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patientsRBC-TI was achieved by 33% (6/18) of evaluable transfusion dependent patients receiving R289 doses ≥500 mg QD, including 40% (2/5) in the 500 mg BID dose groupSOUTH SAN FRANCISCO, Calif.,...
Themefolio
Profiler
Peergroup
© PR Newswire
26.11.2025
RIGL
LISTED
NASDAQ
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Piper Sandler 37th Annual Healthcare Conference...
Themefolio
Profiler
Peergroup
© PR Newswire
17.11.2025
RIGL
LISTED
NASDAQ
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
News Preview
Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad range of patients with R/R mIDH1 AML, including those previously treated with venetoclax-based regimens
Rigel advances its strategic coll...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
12.11.2025
RIGL
LISTED
NASDAQ
Rigel to Present at the Jefferies Global Healthcare Conference in London
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
04.11.2025
RIGL
LISTED
NASDAQ
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Third quarter 2025 total revenue of approximately $69.5 million, including record net product sales of $64.1 million and contract revenues from collaborations of $5.4 million
Generated $27.9 million of net income in the third quarter...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
RIGL
LISTED
NASDAQ
Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition
News Preview
Oral presentation to feature updated data from the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed or refractory lower-risk MDS
Four poster presentations will exhibit new REZLIDHIA® (o...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
RIGL
LISTED
NASDAQ
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update
News Preview
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2025 financial results after market close on Tuesday, November 4, 2025. Rigel senior management will follow the announcement with a live conference call and w...
Themefolio
Profiler
Peergroup
© PR Newswire
08.10.2025
RIGL
LISTED
NASDAQ
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS
News Preview
Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk MDS
SOUTH SAN FRANCISCO, Calif., Oct. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechn...
Themefolio
Profiler
Peergroup
© PR Newswire
03.10.2025
RIGL
LISTED
NASDAQ
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Oct. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement m...
Themefolio
Profiler
Peergroup
© PR Newswire
26.08.2025
RIGL
LISTED
NASDAQ
Rigel to Participate in Upcoming September Investor Conferences
News Preview
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will partici...
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
RIGL
LISTED
NASDAQ
Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update
News Preview
SOUTH SAN FRANCISCO, Calif., July 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2025 financial results after market close on Tuesday, August 5, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1...
Themefolio
Profiler
Peergroup
© PR Newswire
07.07.2025
RIGL
LISTED
NASDAQ
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., July 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering int...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
28.05.2025
RIGL
LISTED
NASDAQ
Rigel to Present at the Jefferies Global Healthcare Conference
News Preview
SOUTH SAN FRANCISCO, Calif., May 28, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday...
Themefolio
Profiler
Peergroup
© PR Newswire
22.05.2025
RIGL
LISTED
NASDAQ
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress
News Preview
Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AMLSOUTH SAN FRANCISCO, Calif., May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company...
Themefolio
Profiler
Peergroup
© PR Newswire
06.05.2025
RIGL
LISTED
NASDAQ
Rigel Reports First Quarter 2025 Financial Results and Provides Business Update
News Preview
First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of net income in the first quarter of 2025R289 granted Orphan Drug designation for the treatment of MDS and Fast Track designation for the treatment of...
Themefolio
Profiler
Peergroup
© PR Newswire
29.04.2025
RIGL
LISTED
NASDAQ
Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update
News Preview
SOUTH SAN FRANCISCO, Calif., April 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30...
Themefolio
Profiler
Peergroup
© PR Newswire
04.04.2025
RIGL
LISTED
NASDAQ
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering in...
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
RIGL
LISTED
NASDAQ
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation
News Preview
SOUTH SAN FRANCISCO, Calif., March 27, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc. (collectively "Annora") resolving patent litigation related to Rigel's product TAVALISSE® (fostamatinib disod...
Themefolio
Profiler
Peergroup
© PR Newswire
10.03.2025
RIGL
LISTED
NASDAQ
Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors
News Preview
SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist and brings more than 25 years of experience developing cellular immunotherapies to treat cancer, including deep expertis...
Themefolio
Profiler
Peergroup
© PR Newswire
04.03.2025
RIGL
LISTED
NASDAQ
Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
News Preview
Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million 2024 total revenue of approximately $179.3 million, which includes TAVALISSE® net product sales of $104.8 million, REZLIDHIA® ne...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
RIGL
LISTED
NASDAQ
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update
News Preview
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2024 financial results after market close on Tuesday, March 4, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Ea...
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2025
RIGL
LISTED
NASDAQ
Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease
News Preview
First patient enrolled in NIH/NHLBI-sponsored Phase 1 Study of fostamatinib, Rigel's oral SYK inhibitor
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of escalating doses of fostamati...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
RIGL
LISTED
NASDAQ
Rigel Provides Business Update and 2025 Outlook
News Preview
Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million R289 granted Orphan Drug designation by the FDA for the treatment of MDSRigel anticipates 2025 total revenue of appro...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
RIGL
LISTED
NASDAQ
Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
SOUTH SAN FRANCISCO, Calif., Jan. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Th...
Themefolio
Profiler
Peergroup
© PR Newswire
03.01.2025
RIGL
LISTED
NASDAQ
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Jan. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering int...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2024
RIGL
LISTED
NASDAQ
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition
News Preview
R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patientsRBC-TI/HI-E responses occurred in 40% of evaluable TD patients receiving R289 doses ≥500 mg QDSOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stag...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2024
RIGL
LISTED
NASDAQ
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
News Preview
SOUTH SAN FRANCISCO, Calif., Dec. 2, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to R289 for the treatment of patients with previously-treate...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2024
RIGL
LISTED
NASDAQ
Rigel to Present at the Jefferies London Healthcare Conference
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Jefferies London Healthcare Conference on Tues...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
RIGL
LISTED
NASDAQ
Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update
News Preview
Third quarter total revenue of $55.3 million, which includes TAVALISSE® net product sales of $26.3 million, REZLIDHIA® net product sales of $5.5 million and GAVRETO® net product sales of $7.1 million Entered into an agreement with Kissei to develop and commercialize REZLIDHIA in all potential indications in Japan, the Republic of Korea and Taiwan...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2024
RIGL
LISTED
NASDAQ
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition
News Preview
- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS- Additional data for REZLIDHIA® (olutasidenib) in patients with mIDH1 AML and MDS
SOUTH SAN FRANCISCO, Calif., Nov. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hemato...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
RIGL
LISTED
NASDAQ
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update
News Preview
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2024
RIGL
LISTED
NASDAQ
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)
News Preview
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it is issuing a Dear Health Care Provider (DHCP) letter related to a new safety signal for GAVRETO® (pralsetinib) after consultation...
Themefolio
Profiler
Peergroup
© PR Newswire
04.10.2024
RIGL
LISTED
NASDAQ
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Oct. 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel,...
Themefolio
Profiler
Peergroup
© PR Newswire
12.09.2024
RIGL
LISTED
NASDAQ
Rigel to Present at the 2024 Cantor Global Healthcare Conference
News Preview
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Cantor Global Healthcare Conference on Thursday,...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2024
RIGL
LISTED
NASDAQ
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML
News Preview
First trial in Rigel's multi-year strategic development alliance with MD Anderson Phase 1b/2 trial of decitabine and venetoclax in combination with Rigel's targeted mIDH1 inhibitor REZLIDHIA for patients with mIDH1 AMLSOUTH SAN FRANCISCO, Calif., Sept. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechn...
Themefolio
Profiler
Peergroup
© PR Newswire
29.08.2024
RIGL
LISTED
NASDAQ
Rigel to Participate in Upcoming September Investor Conferences
News Preview
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September:
2024 Wells Fargo...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
